Sharp Therapeutics Corp. (TSXV:SHRX)
Canada flag Canada · Delayed Price · Currency is CAD
1.850
0.00 (0.00%)
At close: Apr 30, 2025

Sharp Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
0.740.440.510.55
Research & Development
2.472.091.731.79
Operating Expenses
3.252.542.272.42
Operating Income
-3.25-2.54-2.27-2.42
Interest Expense
-0.17-0.17-0.17-0.18
Other Non Operating Income (Expenses)
-1.91-0.27-0.58-0.65
EBT Excluding Unusual Items
-5.33-2.98-3.02-3.24
Other Unusual Items
0.05-0.28-0.54-0.64
Pretax Income
-5.29-3.26-3.56-3.88
Net Income
-5.29-3.26-3.56-3.88
Net Income to Common
-5.29-3.26-3.56-3.88
Shares Outstanding (Basic)
16940
Shares Outstanding (Diluted)
16940
Shares Change (YoY)
11406.81%107.12%3028.62%-
EPS (Basic)
-0.33-0.36-0.82-27.97
EPS (Diluted)
-0.34-0.36-0.82-27.97
Free Cash Flow
-4.39-3.63-1.97-2.05
Free Cash Flow Per Share
-0.27-0.40-0.45-14.77
EBITDA
-3.25-2.52-2.24-2.37
D&A For EBITDA
00.020.030.05
EBIT
-3.25-2.54-2.27-2.42
Source: S&P Global Market Intelligence. Standard template. Financial Sources.